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Abstract
Background: In Vietnam, no systematic prenatal toxoplasmosis screening is in place, and only few studies have assessed
the prevalence and importance of this zoonotic parasite infection. In addition, no studies have been conducted to assess
the risk factors associated with toxoplasmosis. This study protocol was developed to determine the seroprevalence of
toxoplasmosis in pregnant women in Hanoi and Thai Binh, Northern Vietnam, and to evaluate the association with risk
factors and congenital toxoplasmosis. The protocol was developed in a way that it could potentially evolve into a
countrywide prenatal diagnosis and prevention program, with the main focus on primary prevention.
Methods: The collaborating gynaecologists will invite eligible pregnant women attending antenatal care for the first
time to participate in the study. At first consult, information about toxoplasmosis and its prevention will be provided. All
participants will be asked to fill in a questionnaire, which is designed to analyse socio-demographic and biologically
plausible risk factors associated with toxoplasmosis, and blood samples will be collected to determine the seroprevalence
of toxoplasmosis in pregnant women. In case there is suspicion of a primary infection during pregnancy, the concerned
women will be followed-up by the gynaecologists according to a predefined protocol. Every participant will be informed
on her serological status, risk factors and prevention measures and is offered appropriate medical information and
medical follow-up if required.
Discussion: The hypothesis is that congenital toxoplasmosis is an important but currently under-diagnosed public health
problem in Vietnam. This study can strengthen sustainable control of toxoplasmosis in Vietnam, provide a protocol for
prenatal diagnosis, boost overall awareness, improve the knowledge about toxoplasmosis prevention and can be
essential for evidence-based health policy.
Keywords: Congenital toxoplasmosis, Toxoplasmosis during pregnancy, Prenatal diagnostics, Serology, Prevention,
Vietnam
Background
Toxoplasmosis is a zoonosis caused by Toxoplasma gon-
dii, a protozoan parasite, with felids as definitive hosts and
warm-blooded animals as intermediate hosts. Humans get
infected with T. gondii after consumption of raw or under-
cooked meat or ingestion of cat-shed oocysts via contami-
nated soil, food or water; or congenitally by transplacental
transmission of tachyzoites [1, 2]. Congenital toxoplasmo-
sis is asymptomatic in most cases but it can also result in
fetal or neonatal death or various congenital defects, such
as hydrocephalus, central nervous system abnormalities
and chorioretinitis [3–5]. Acquired toxoplasmosis can
cause serious disease in immunocompromised patients [6]
but usually results in a relatively mild acute illness in
immunocompetent individuals with some cases suffering
fatigue and/or acquired chorioretinitis. However, there is
increasing evidence that it may also result in a number of
neurological or psychiatric diseases [7, 8].
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The Foodborne Disease Burden Epidemiology Reference
Group (FERG) ranked T. gondii as the 13th most import-
ant cause of foodborne diseases globally [9]. Congenital
toxoplasmosis has an estimated global incidence of 1.5
(95% credibility interval (CI) 1.4–1.6) cases per 1000 live
births, resulting in a burden of 9.6 (95% CI 5.8–15)
Disability-Adjusted Life Years (DALYs) per 1000 live births
[5]. The presence of cats, alimentary habits, hygienic con-
ditions and the climate can cause the variation seen in
prevalence in humans in different countries and within
countries from one region to another [10–13].
Since congenital toxoplasmosis can only occur when a
woman is primarily infected with T. gondii during preg-
nancy, it can be important to know her serological status
at the beginning of pregnancy. Women who are seroposi-
tive have no risk for congenital toxoplasmosis and preven-
tion measures can seriously reduce the risk of infection
during pregnancy in seronegative women. Breugelmans et
al. [14] concluded that the promotion of simple primary
prevention measures is very effective in the prevention of
toxoplasmosis during pregnancy. For these measures to be
successful in the local context it is important to know the
major risk factors associated with the infection.
Until now, few studies have been conducted on the
prevalence and importance of toxoplasmosis in Vietnam,
a densely populated country in southeast Asia with a
population of around 93.5 million in 2015 [15]. Studies
conducted between 1959 and 2003 showed a toxoplas-
mosis prevalence ranging from 7.7 to 29% in the general
population and 11% in pregnant women [16, 17]. In a
sero-survey on toxoplasmosis in rural areas of the north-
ern provinces, Nghe An, Lao Cai and Tien Giang, a
seroprevalence of 4.2% was found [18]. In animals, a
seroprevalence of 27% was found in pigs [19] and of 11
and 3.0% in cattle and water buffaloes, respectively [20].
However, currently no systematic prenatal screening of
toxoplasmosis is in place and no studies have assessed the
risk factors associated with toxoplasmosis in Vietnam.
Therefore, this study is aimed to determine the seropreva-
lence of toxoplasmosis in pregnant women in Hanoi and
Thai Binh, Northern Vietnam, and to evaluate the associ-
ation with risk factors and congenital toxoplasmosis. In
addition, the protocol was developed in a way that it could
potentially evolve into a countrywide prenatal diagnosis
and prevention program, with the main focus on primary
prevention.
Methods
Study sites and subject related procedures
The study will be conducted in collaboration with The
Parasitology Department of the National Institute of
Malariology, Parasitology and Entomology (NIMPE) in
Hanoi, and the serological tests will be carried out in
their laboratory. The two study sites are the National
Hospital of Obstetrics and Gynaecology in Hanoi, one of
the leading hospitals in Vietnam for obstetrics and gynae-
cology, and the Hospital of Obstetrics and Gynaecology in
the Thai Binh province (120 km south east of Hanoi). In
the first hospital approximately 200–300 pregnant women
present for consultation and follow-up each day and in
the second hospital around 150. Vietnam allows families
to have a maximum of two children (decision no 162-
HDBT, date 18 October 1988), which induced a decrease
in the population size over the years. The country showed
a crude birth rate of 16.2, with 15.3 in urban areas and
16.7 in rural areas in 2015. The age-specific fertility rate
was 24 per 1000 women in the age category 15–19 years
in 2009, compared to the highest rates of 121 and 133 per
1000 women in the age categories 20–24 and 25–29 years,
respectively [15]. Hanoi, with geographical location (21°.2′
N, 105°51′E), has a population size of 7.2 million and Thai
Binh province, with geographical location (20° 30′N, 106°
20′E), has a population size of 1.8 million approximately
[15]. In contrast to the rest of Vietnam, Thai Binh has a
dense cat population, which consist of pets, street cats,
and cats for meat consumption. Thai Binh is therefore
also known as the “cat province” [21].
The cooperating gynaecologists will identify eligible
pregnant women attending the antenatal care for the
first time during the specified study period. In order to
be eligible, study participants must meet the following
criteria: pregnant woman; between 16 and 48 years old;
gestational age ranging from 0 to 14 weeks; HIV nega-
tive; follow-up of pregnancy by one of the collaborating
gynaecologists of the collaborating hospitals; willingness
to participate during the total duration of pregnancy and
if necessary after birth; willing and able to provide writ-
ten informed consent (by signature of the patient or, in
case the person is illiterate, by thumbprint and a signa-
ture of an impartial witness).
Both hospitals are public hospitals, accessible for women
of all layers of the society. Women in Vietnam, especially
in urban areas, tend to go the gynaecologist from the mo-
ment they suspect to be pregnant and go for follow up
consultation and ultrasound every month until delivery.
Since the study will only include pregnant women attend-
ing antenatal care for the first time it is unlikely we will
have an overrepresentation of women with potential com-
plications. Therefore, we believe that both the hospitals in
Hanoi and Thai Binh can recruit a representative popula-
tion of pregnant women.
Assuming an expected prevalence of 50% and an abso-
lute precision of 5% at a 95% confidence level, the re-
quired sample size for estimating the seroprevalence in
eligible pregnant women should be at least 385 per hos-
pital [22]. To account for a small number of potential
dropouts (which will be avoided as much as possible) we
decided to increase the sample size to 400 per hospital.
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At the first consult awareness will be raised on the
importance of toxoplasmosis and its possible conse-
quences on pregnancy. The benefits and risks for preg-
nant women to know their serological status will be
explained and they will be asked by their gynaecologist
to participate in the study and to fill in the informed
consent form (see Additional file 1). In addition, they
will receive an information folder in Vietnamese includ-
ing prevention measures for toxoplasmosis, which will
be reiterated mid-gestation (see Additional file 2). Partic-
ipants will be asked to fill in a structured questionnaire
to detect socio-demographic and biologically plausible
risk factors associated with toxoplasmosis, awareness,
clinical history and presentation of signs and symptoms
relating to toxoplasmosis (see Additional file 3). During
the same consult 5 ml blood will be collected from par-
ticipating women by the gynaecologist in the hospital.
Laboratory procedures
The blood will be collected in labelled tubes (with hos-
pital code, identification code of participant, and sample
number) and transferred in cool boxes on ice to the la-
boratory of the Parasitology Department, NIMPE, for
testing within a week following sampling. Serum samples
can be stored for up to 5 days at 2–8 °C; if longer
storage is required, they can be frozen at −25 ± 6 °C.
After separation of the serum by centrifugation, all sam-
ples will be tested for specific anti-Toxoplasma IgG by
the Toxoscreen Direct Agglutination kit (BioMérieux,
Marcy-l’Etoile, France) according to the manufacturers’
instructions. Screening of antibodies will be done on 1/
40 and 1/4000 serum dilutions, the latter to monitor for
a possible prozone effect at the 1/40 dilution.
To detect recent infections an IgM test will be conducted
using the ISAGA kit (Immunoglobulin-M immunosorbent
agglutination assay, BioMérieux, Marcy-l’Etoile, France),
according to the manufacturers’ instructions. Detection of
IgM and IgG is possible after approximately 2 and 4 weeks
after infection, respectively. IgM is detectable by ISAGA
for approximately a year (median 12.8 months, interquar-
tile range 6.9–24.9) whereas IgG persists lifelong in im-
munocompetent people [23–25].
Women that test positive for IgG only are considered
seropositive and thus immune. Women who are IgM posi-
tive will be tested again for IgG and IgM 3–4 weeks later
(Fig. 1). An IgG negative and IgM positive test result in the
first test and an IgG positive test result 3–4 or 6–8 weeks
later is indicative for seroconversion. When positive for
IgG and IgM in the first test an IgG avidity test (on the first
serum sample; performed in the National Hospital of
Obstetrics and Gynaecology in Hanoi) will be done to
determine the time of seroconversion.
The IgG avidity test measures the aggregate strength
with which the antibodies bind to the antigens. The affinity
increases over time of infection, which means high avidity
indicates an old infection (>3 months ago). Low avidity can
be an indication of recent infection, but some individuals
have persistent low IgG avidity for many months after in-
fection, which means it cannot be used alone to determine
whether the infection was recently acquired [26].
At any suspicion of seroconversion, women will be
followed-up (including an ultrasound every 4 weeks) by
their treating gynaecologist. The gynaecologist will make
sure these women will be advised correctly about the risks
of transmission to the foetus, the risk of symptoms when
there is a congenital infection, the steps that will have to
be taken during follow-up, and all worries/anxieties/guilt
will be carefully discussed and put into perspective. Amni-
otic fluid PCR can be performed starting from 18 weeks
of gestation onwards and at least 8 weeks after diagnosis
of seroconversion. The risk of the procedure should be
carefully weighed against the potential benefit of diagnos-
ing fetal infection [27].
Women that test negative for toxoplasmosis specific
IgG and IgM in the first test will be informed by their gy-
naecologist about (congenital) toxoplasmosis as a disease
and what measures should be taken to avoid toxoplasmo-
sis during pregnancy. A folder (in Vietnamese) will be
handed out to all participants explaining (congenital)
toxoplasmosis and its prevention. These recommenda-
tions will be reiterated to seronegative women at around
mid-gestation.
If there is any indication for congenital toxoplasmosis,
NIMPE will make sure that the child will be correctly in-
vestigated and followed-up for any signs and symptoms of
congenital toxoplasmosis by a neonatologist/paediatrician
of the parents’ choice. For serology, blood samples will be
collected by the treating neonatologist/paediatrician
within 2 days and tested for toxoplasmosis specific IgM,
IgA (performed in Belgium) and IgG. This will be repeated
after 10 days and every month up to 4 months, and then
at 6, 9 and 12 months after birth. NIMPE will take care of
the follow-up serology and will give all necessary support
to the treating paediatrician and parents. The presence of
IgM and IgA in neonatal serum is diagnostic for congeni-
tal toxoplasmosis. However, the sensitivity is low and
decreases when the infection occurred early during preg-
nancy. Persisting IgG antibodies 9 months to 1 year after
birth are an indication for congenital toxoplasmosis but
only if the mother is also found IgG positive in the peri-
natal period [28].
Table 1 shows an overview of the activities during the
different antenatal consults. A detailed patient form
should be filled in for every patient by the treating
gynaecologist (see Additional file 4) and if follow-up
and additional medical care is necessary, the gynae-
cologist can consult the provided doctors’ form with
the most important information, including diagnostics,
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prognostics and options for treatment (available from
the authors upon request).
After finalization of each laboratory test, a picture will be
made of the Toxoscreen-DA and ISAGA plates for docu-
mentation purposes and for interpretation support. All
serum samples (frozen at −25 ± 6 °C) and documents will
be retained at NIMPE for 5 years after the completion of
the study, which assures the possibility to retrospectively
look back at the results in case an asymptomatic child at
birth shows any symptoms later in life.
The laboratory of the Parasitology Department, NIMPE,
has received the ISO Certificate VILAS no 924 in May
2016. Local investigators will ensure compliance with pro-
tocols and quality of samples, documentation and ana-
lyzes. The results will always be validated according to the
verification procedure set up in the lab for quality control.
Fig. 1 Diagnostic flowchart of congenital Toxoplasma gondii infection. Adapted from Van Haesebrouck et al. [28] and Montoya and Remington
[27]. #Low avidity can be an indication of recent infection but should not be directly interpreted as recent infection [26]. *Amniotic fluid PCR can
be performed starting from 18 weeks of gestation onwards and at least 8 weeks after diagnosis of seroconversion. The risk of the procedure should be
carefully weighed against the potential benefit of diagnosing fetal infection [27]. pos, positive; neg, negative; US, ultrasound; PCR, polymerase chain
reaction; TGS, Toxoplasma gondii specific
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Data analysis
Data from the source documents will be entered in
Microsoft Excel 2011 and access to the file will be
protected by a password. Data and results will be han-
dled confidentially and privacy of participants will be
assured. All personal information is only documented
in the file of the treating gynaecologist and will be
encoded by a unique patient number. These codes will
be linked to the respective informed consents, ques-
tionnaires, samples and patients’ forms thereby blinding
investigators to direct identification of the data. The
results of the blood testing will be communicated to
the treating gynaecologists and from there to the
participating women.
Cross-sectional studies are observational and descriptive
studies and can be used to describe the seroprevalence
and risk factors. In the group where there is suspicion of a
seroconversion, the respective women will be followed-up
(longitudinal) by their gynecologists.
The seroprevalence of toxoplasmosis in pregnant
women in Hanoi and Thai Binh will be determined and
a comparison will be made between these two regions.
The overall incidence of toxoplasmosis can be calculated
using a disease transmission model. The simplest disease
transmission model is the so-called catalytic model,
which divides the population into a seronegative and
seropositive compartment. The rate at which seronega-
tive individuals become positive over time is called the
force of infection (λ), and is directly related to the over-
all incidence. Under the assumption of lifelong immun-
ity and homogenous transmission dynamics over time, it
can be shown that the age-specific seroprevalence π(a) is
related to the age-specific force of infection λ(a). As a
result, the force of infection can be statistically deter-
mined from the age-specific seroprevalence. The sim-
plest model assumes an identical force of infection for
each age group (i.e., λ(a) = λ) [29]. In reality, however,
this assumption is not always accurate. Therefore, the
force of infection can also be modelled as a linear or
quadratic function, or, more flexibly, using fractional
polynomials or splines [30]. We will choose the model
that best suits the data.
Based on the incidence in the pregnant women, the in-
cidence of congenital cases will be estimated. For toxo-
plasmosis it is commonly assumed that only primo-
infection of seronegative mothers may lead to congenital
infections [31]. The incidence of this congenital infection
will depend on the force of infection, the age-specific
seroprevalence of women, and the risk of trans-placental
transfer of the pathogen. In addition, we will be able to
assess the incidence of toxoplasmosis during the first tri-
mester of pregnancy and the related incidence of con-
genital infections due to the follow-up of women that
test positive for toxoplasmosis related IgM. Based on the
information on the incidence in the first trimester, com-
bined with information on the percentage of congenital
infections seen in the first trimester [24] we can estimate
the total incidence of congenital toxoplasmosis and this
can be verified with the estimated incidence based on
seroprevalence data. By combining the incidence estimate
with information on the clinical impact from Torgerson
and Mastroiacovo [5] and we will be able to estimate the
public health impact of congenital toxoplasmosis in
Northern Vietnam in terms of DALYs, which combine
disease occurrence and clinical impact in a single
number [32]. And by combining incidence estimates
with the costs related to the protocol we will be able
to assess the cost-effectiveness of this screening and
prevention program.
The questionnaire will be analysed to detect socio-
demographic and biologically plausible risk factors asso-
ciated with toxoplasmosis, awareness, clinical history
and presentation of signs and symptoms relating to
toxoplasmosis. Multivariable analyses will be performed to
investigate the association between T. gondii seropositivity
as a dependent variable and possible demographic and risk
factors as independent variables. To account for the study
design, data analysis will be based on generalized linear
Table 1 Overview of the activities during the different antenatal consults
C1
Enrolment
C2
(3–4 weeks after C1)
C3
(6–8 weeks after C1)
C Mid gestation N1
Postnatal
Eligibility screen X
Informed consent X
Questionnaire X
Information folder about toxoplasmosis
and its prevention
X Xc
Patient anamnesis X
Clinical examination X X X X X
Blood sample for serology X Xa Xb
Blood sample from new-born for serology Xd
aIf IgM positive; bIf IgG negative and IgM positive at C1 and C2; cIf seronegative; dIf suspicious for congenital toxoplasmosis. C prenatal consult, N neonatal consult
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models. All calculations will be performed in R 3.3.1 at the
Institute of Tropical Medicine (ITM) in collaboration with
NIMPE [33].
Discussion
We hypothesise that the majority of the women of child-
bearing age will be seronegative in Vietnam, which
makes dissemination of information about primary pre-
vention an extremely important part of the study. We
assume that the second largest group will be the sero-
positive women who are immune. A small group is as-
sumed to have a seroconversion during pregnancy; this
group requires appropriate medical care and follow-up.
Special care has to be given to women with a positive
HIV status. In Vietnam, the prevalence of HIV is low.
UNAIDS estimates of 2015 show a HIV prevalence rate
of 0.5% [0.4–0.6%] in adults aged 15 to 49 years old [34].
Pregnant women are normally tested for HIV at the last
antenatal consult before labour in our study sites. If the
HIV status is already known at first antenatal consult,
HIV positive women will be excluded from this study.
However, prevention measures, which are of utmost im-
portance in this group, will still be communicated. In
addition, diagnostics for toxoplasmosis can still be car-
ried out by NIMPE and correct medical follow-up and
prophylaxis will be secured by the treating gynaecologist,
according to the Vietnamese guidelines [35]. The neonatal
ward should be notified about the use of trimethoprim-
sulfamethoxazole or sulfadiazine in the mother near the
time of delivery for early detection of hyperbilirubinaemia
and kernicterus in the new-born.
If the HIV status was not known at first antenatal con-
sult and the HIV test before labour turns out to be posi-
tive, this individual is excluded from the study. However,
both a retrospective analysis of the toxoplasmosis serology
and a new blood sample and diagnostics for toxoplasmosis
will be carried out. Because negative T. gondii test results
are seen in patients with abnormalities of B cell function,
false negative results in HIV positive women are possible
[36]. Pregnant women with primary toxoplasmosis have
high risk of transmitting the infection to the fetus; the risk
of transmission in reactivation of maternal infection due
to HIV caused immunosuppression is lower [37]. The
treating gynaecologist should perform ultrasound examin-
ation of pregnant women with HIV and toxoplasmosis for
detection of hydrocephalus, cerebral calcifications, fetal
growth restriction and other congenital toxoplasmosis re-
lated abnormalities. Furthermore, all children born to
women with HIV need careful and thorough inspection
and follow-up for any signs and symptoms of congenital
toxoplasmosis and should be treated according to the
diagnostic outcome by a pediatrician.
This project aims to strengthen sustainable control
of toxoplasmosis in Vietnam. The hypothesis is that
congenital toxoplasmosis is an important but currently
under-diagnosed public health problem. Congenital toxo-
plasmosis not only potentially has a significant incidence
in Vietnam but also induces long-term sequelae from an
early age and thus has an important impact on the lives of
patients and their families. We hypothesize that the sero-
prevalence is higher in Thai Binh compared to Hanoi due
to the high cat population in the former. The seroconver-
sion rate in pregnant women does not necessarily increase
with a higher seroprevalence, since this depends on the
age specific seroprevalence and incidence in women of
childbearing age. A (single) serological screening for T.
gondii antibodies can be recommended in women of
child-bearing age as it allows identification of women at
risk of acquiring infection and can be part of a strategic
approach for the prevention of congenital toxoplasmosis
[27, 38]. In addition, toxoplasmosis seroprevalence is
continuously evolving, subject to regional socioeconomic
parameters and population (health related) habits. Aware-
ness of these trends, may guide the development of public
health policies [39].
Environmental factors such as seasonal variation and
variations due to rainfall might influence the force of in-
fection [12, 40, 41]. However, we decided to focus our
questionnaire on risk factors that can be influenced by
awareness and implementation of prevention measures
based on behavior. Our estimates will provide insights in
the seroprevalence of toxoplasmosis in pregnant women
and can provide a baseline against which future evolu-
tions, e.g., associated with changing awareness, socioeco-
nomic or environmental conditions, can be monitored.
This study will provide much needed information on
T. gondii infection rates in pregnant women in Hanoi
and Thai Binh. It will also establish a better understand-
ing of toxoplasmosis epidemiology in pregnant women,
thereby enabling a more structured and integrated con-
trol and prevention approach to reduce the risk of trans-
mission and prevalence of this zoonosis. Furthermore, it
will provide an assessment of the suitability and impact of
toxoplasmosis screening and prevention information dis-
semination as an approach to the control of congenital
toxoplasmosis, as well as a protocol that could potentially
evolve into a countrywide prenatal diagnosis and preven-
tion program, with the main focus on primary prevention.
Different screening strategies have been proposed in
several settings differing in Toxoplasma epidemiological
status, T. gondii strain and medical recourses, infrastruc-
ture and organization [38, 42–44]. This protocol can be
used in similar settings and the choice of diagnostic test
can be altered based on the resources, laboratory infra-
structure, and experience. The ISAGA used in this study,
ensures very early detection of IgM in a seroconversion
and the test is very sensitive to residual IgM, while residual
IgM can persist for periods of more than 1 year (according
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to the manufacturers’ instructions). Our protocol takes this
into account by testing an IgG negative and IgM positive
patient again 3–4 weeks later to identify IgG seroconver-
sion and even a third time (6–8 weeks after the first test) if
necessary. In case of residual IgM, our protocol describes
to do an IgG avidity test to determine the time of serocon-
version. The interpretation of the results should always be
made taking into account the patient’s history and the re-
sults of all (other) tests performed. Since we acknowledge
the diagnosis of toxoplasmosis can be complicated and
may vary from person to person, our protocol allows
retesting a sample with another test to compare outcomes
if necessary and if there is any suspicion of seroconversion
during pregnancy women will be thoroughly followed up
(including an ultrasound every 4 weeks).
On the individual level, every participant will be in-
formed on the test results and will be offered appropri-
ate medical information and medical follow-up if
required. In this way, every individual will know her
serological status, risk factors and prevention measures.
All participants in the study will be informed of the
overall research findings once the project is completed.
In the long term, this study will contribute to increased
knowledge and awareness of toxoplasmosis and its pre-
vention and a reduction in the incidence of congenital
toxoplasmosis, which can contribute towards sustainable
development goal three by reducing child morbidity and
mortality [45]. In addition, it is essential for evidence-
based health policy, which can induce an important public
health improvement and can reduce healthcare costs.
Finally, information about the impact of this infection is
of utmost importance for prioritizing the development of
much needed prevention and intervention measures.
Therefore, this project is a prerequisite for every further
step forward.
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